Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SynAct Pharma ABOSTO:SYNACT +7.25%32 EV-to-OCF is -9.70 as of Aug. 20, 2026. GuruFocus rates OSTO:SYNACT with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 1,409 Biotechnology companies, SynAct Pharma AB ranks better than 70.26% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, SynAct Pharma AB's Enterprise Value is kr1,136.45 Mil.
SynAct Pharma AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was kr-117.21 Mil. Therefore, SynAct Pharma AB's EV-to-OCF for today is -9.70.
The historical rank and industry rank for SynAct Pharma AB's EV-to-OCF or its related term are showing as below:
OSTO:SYNACT'
s EV-to-OCF Range Over the Past 10 Years
Min: -10.37 Med: 0 Max: -10.37
Current: -10.37
During the past 10 years, the highest EV-to-OCF of SynAct Pharma AB was -10.37. The lowest was -10.37. And the median was .
OSTO:SYNACT's EV-to-OCF is ranked better than 70.26% of 1409
companies
in the Biotechnology industry
Industry Median: -3.66
vs OSTO:SYNACT: -10.37
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SynAct Pharma AB (OSTO:SYNACT) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SynAct Pharma AB's PE Ratio (TTM) for today is calculated as:
SynAct Pharma AB's share price for today is kr21.45.
SynAct Pharma AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-49.490.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
SynAct Pharma AB EV-to-OCF Related Terms
SynAct Pharma AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for SynAct Pharma AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:SYNACT vs VRTX, REGN, RVMD: EV-to-OCF Comparison
For the Biotechnology subindustry, SynAct Pharma AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SynAct Pharma AB EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where SynAct Pharma AB's EV-to-OCF falls into.
SynAct Pharma AB's current Enterprise Value is kr1,136.45 Mil.
SynAct Pharma AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-117.21 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SynAct Pharma AB (OSTO:SYNACT) has a EV-to-OCF of -9.70 as of Aug. 20, 2026. According to the industry distribution chart, SynAct Pharma AB ranks #419 out of 1409 companies in the Biotechnology industry, placing it in the top 29.7%.
Is SynAct Pharma AB's EV-to-OCF too high?
SynAct Pharma AB's current EV-to-OCF is -9.70. Based on the distribution chart, SynAct Pharma AB ranks #419 out of 1409 companies in the Biotechnology industry, which is above the industry midpoint. Overall, SynAct Pharma AB has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does SynAct Pharma AB's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, SynAct Pharma AB ranks #419 out of 1409 companies for EV-to-OCF. This puts SynAct Pharma AB in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. SynAct Pharma AB's current EV-to-OCF is -9.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SynAct Pharma AB stock overvalued right now?
SynAct Pharma AB (OSTO:SYNACT) has a current EV-to-OCF of -9.70. The current EV-to-OCF is -9.70. SynAct Pharma AB's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For SynAct Pharma AB (OSTO:SYNACT), the current EV-to-OCF is -9.70 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SynAct Pharma AB is a clinical-stage biotechnology company focused on resolving inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation-resolution activity to help patients achieve immune balance and overcome inflammation. AP1189, the company's drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.
32GF Score
Get the complete analysis for OSTO:SYNACT
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:SYNACT has been successfully added to your 
